EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Safety and Efficacy of Commercial Porcine Vaccines Against Mycoplasma hyopneumoniae and Porcine Circovirus Type 2 (PCV2)

Meritxell Simon-Grifé, Alexandra Moros iD, Cecilia Pedernera, Ester Puigvert, Lucía Acal, Elena Plantalech, Mercè Roca, Jordi Montané, Ricard March iD, Marta Sitjà

Animals · 06.03.2026 · 16 (5) · 830

DOI: 10.3390/ani16050830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animals, online erschienen am 06.03.2026. Verfasst von Meritxell Simon-Grifé und 9 weiteren Autor:innen. Beteiligte Einrichtung: HIPRA S.A., Avda. La Selva 135, Amer, 17170 Girona, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HIPRA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycoplasma hyopneumoniae (Mhyo) and porcine circovirus type 2 (PCV2) infections cause enormous economic losses in the swine production sector. Vaccination remains the most effective strategy against the complex clinical entities caused by these pathogens. While effective vaccines against PCV2 are available, immunisation against Mhyo continues to be challenging. In parallel, intradermal (ID) vaccination can optimise time and costs while providing faster and user-safe administration. This study compares the safety and efficacy of commercial porcine vaccines against Mhyo and PCV2, including intramuscular (IM) and ID ones: (1) ID recombinant Mhyo-PCV2, (2) ID recombinant PCV2 + ID inactivated Mhyo, (3) IM bivalent inactivated Mhyo and recombinant PCV2, (4) IM bivalent inactivated Mhyo and inactivated chimeric PCV1-PCV2 and (5) IM inactivated Mhyo + IM inactivated PCV2. Safety, evaluated through clinical signs, adverse effects, local reactions, and average daily weight gain, has been confirmed for all vaccines. Following challenge with both pathogens, all products reduced PCV2 viremia and faecal shedding, proving efficacy against PCV2 infection. In contrast, only the ID recombinant Mhyo-PCV2 and the IM inactivated Mhyo + IM inactivated PCV2 vaccines, significantly reduced lung lesions related to Mhyo infection, indicating a better protection compared to the other vaccines.

Schlagwörter

Stichwörter der Autor:innen

Mycoplasma hyopneumoniaePCV2intradermalpigsporcine circovirusvaccination

Autor:innen und Institutionen

  • HIPRA S.A., Avda. La Selva 135, Amer, 17170 Girona, Spain.

ORCID-Profile: Alexandra Moros, Ricard March

Förderung

  • HIPRA

Zitieren

APA

Simon-Grifé, M., Moros, A., Pedernera, C., Puigvert, E., Acal, L., Plantalech, E., Roca, M., Montané, J., March, R., & Sitjà, M. (2026). Comparative Safety and Efficacy of Commercial Porcine Vaccines Against Mycoplasma hyopneumoniae and Porcine Circovirus Type 2 (PCV2). Animals, 16(5), 830. https://doi.org/10.3390/ani16050830

Vancouver

Simon-Grifé M, Moros A, Pedernera C, Puigvert E, Acal L, Plantalech E, et al. Comparative Safety and Efficacy of Commercial Porcine Vaccines Against Mycoplasma hyopneumoniae and Porcine Circovirus Type 2 (PCV2). Animals. 2026;16(5):830. doi:10.3390/ani16050830

BibTeX
@article{SimonGrif2026,
  author = {Simon-Grifé, Meritxell and Moros, Alexandra and Pedernera, Cecilia and Puigvert, Ester and Acal, Lucía and Plantalech, Elena and Roca, Mercè and Montané, Jordi and March, Ricard and Sitjà, Marta},
  title = {Comparative Safety and Efficacy of Commercial Porcine Vaccines Against Mycoplasma hyopneumoniae and Porcine Circovirus Type 2 (PCV2)},
  journal = {Animals},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {830},
  doi = {10.3390/ani16050830}
}
Kostenlos starten →